207 related articles for article (PubMed ID: 35995581)
1. Androgens, brain and androgen deprivation therapy in paraphilic disorders: A narrative review.
Baltodano-Calle MJ; Onton-Díaz M; Gonzales GF
Andrologia; 2022 Nov; 54(10):e14561. PubMed ID: 35995581
[TBL] [Abstract][Full Text] [Related]
2. Androgen Deprivation Therapy in Pedophilic Disorder: Exploring the Physical, Psychological, and Sexual Effects From a Patient's Perspective.
Boons L; Jeandarme I; Vervaeke G
J Sex Med; 2021 Feb; 18(2):353-362. PubMed ID: 33468446
[TBL] [Abstract][Full Text] [Related]
3. Treatment of Paraphilic Disorders in Sexual Offenders or Men With a Risk of Sexual Offending With Luteinizing Hormone-Releasing Hormone Agonists: An Updated Systematic Review.
Turner D; Briken P
J Sex Med; 2018 Jan; 15(1):77-93. PubMed ID: 29289377
[TBL] [Abstract][Full Text] [Related]
4. Pharmacologic treatment of sex offenders with paraphilic disorder.
Garcia FD; Delavenne HG; Assumpção Ade F; Thibaut F
Curr Psychiatry Rep; 2013 May; 15(5):356. PubMed ID: 23572328
[TBL] [Abstract][Full Text] [Related]
5. The role of testosterone in sexuality and paraphilia--a neurobiological approach. Part II: testosterone and paraphilia.
Jordan K; Fromberger P; Stolpmann G; Müller JL
J Sex Med; 2011 Nov; 8(11):3008-29. PubMed ID: 21797985
[TBL] [Abstract][Full Text] [Related]
6. The impact of androgen deprivation therapy on bone mineral density in men treated for paraphilic disorder: A retrospective cohort study.
De Landtsheer A; Bekaert L; David K; Marcq P; Jeandarme I; Decallonne B; Antonio L; Vanderschueren D
Andrology; 2022 Mar; 10(3):545-550. PubMed ID: 34914863
[TBL] [Abstract][Full Text] [Related]
7. Androgens and prostate cancer; pathogenesis and deprivation therapy.
Grossmann M; Cheung AS; Zajac JD
Best Pract Res Clin Endocrinol Metab; 2013 Aug; 27(4):603-16. PubMed ID: 24054933
[TBL] [Abstract][Full Text] [Related]
8. Cardiovascular Impact of Androgen Deprivation Therapy: from Basic Biology to Clinical Practice.
Kim J; Freeman K; Ayala A; Mullen M; Sun Z; Rhee JW
Curr Oncol Rep; 2023 Sep; 25(9):965-977. PubMed ID: 37273124
[TBL] [Abstract][Full Text] [Related]
9. Advances with androgen deprivation therapy for prostate cancer.
Yu EM; Aragon-Ching JB
Expert Opin Pharmacother; 2022 Jun; 23(9):1015-1033. PubMed ID: 35108137
[TBL] [Abstract][Full Text] [Related]
10. Cardiovascular Toxicity of Androgen Deprivation Therapy.
Boland J; Choi W; Lee M; Lin J
Curr Cardiol Rep; 2021 Jul; 23(8):109. PubMed ID: 34216282
[TBL] [Abstract][Full Text] [Related]
11. The impact of long-term androgen deprivation therapy on cognitive function and socioeconomic decision making in prostate cancer patients.
Holtfrerich SKC; Knipper S; Purwins J; Castens J; Beyer B; Schlomm T; Diekhof EK
Psychooncology; 2020 Aug; 29(8):1338-1346. PubMed ID: 32539186
[TBL] [Abstract][Full Text] [Related]
12. Pharmacological treatments for paraphilic patients and sexual offenders.
Briken P; Kafka MP
Curr Opin Psychiatry; 2007 Nov; 20(6):609-13. PubMed ID: 17921764
[TBL] [Abstract][Full Text] [Related]
13. The Biological Treatment of Paraphilic Disorders: an Updated Review.
Holoyda BJ; Kellaher DC
Curr Psychiatry Rep; 2016 Feb; 18(2):19. PubMed ID: 26800994
[TBL] [Abstract][Full Text] [Related]
14. Drug treatment of paraphilic and nonparaphilic sexual disorders.
Guay DR
Clin Ther; 2009 Jan; 31(1):1-31. PubMed ID: 19243704
[TBL] [Abstract][Full Text] [Related]
15. Sexual Motivators and Endorsement of Models Describing Sexual Response of Men Undergoing Androgen Deprivation Therapy for Advanced Prostate Cancer.
Fode M; Mosholt KS; Nielsen TK; Tolouee S; Giraldi A; Østergren PB; Azawi N
J Sex Med; 2020 Aug; 17(8):1538-1543. PubMed ID: 32448679
[TBL] [Abstract][Full Text] [Related]
16. Pituitary-testis axis dysfunction following adjuvant androgen deprivation therapy.
Abildgaard J; Vincent Stroomberg H; Kirstine Bang A; Albrethsen J; Smedegaard Kruuse L; Juul A; Brasso K; Røder A; Jørgensen N
Endocr Relat Cancer; 2023 Jan; 30(1):. PubMed ID: 36356295
[TBL] [Abstract][Full Text] [Related]
17. Targeting the androgen receptor signaling pathway in advanced prostate cancer.
Chung C; Abboud K
Am J Health Syst Pharm; 2022 Jul; 79(15):1224-1235. PubMed ID: 35390118
[TBL] [Abstract][Full Text] [Related]
18. Potential side effects of androgen deprivation treatment in sex offenders.
Giltay EJ; Gooren LJ
J Am Acad Psychiatry Law; 2009; 37(1):53-8. PubMed ID: 19297634
[TBL] [Abstract][Full Text] [Related]
19. A comparative study on the efficacies of gonadotropin-releasing hormone (GnRH) agonist and GnRH antagonist in neoadjuvant androgen deprivation therapy combined with transperineal prostate brachytherapy for localized prostate cancer.
Miki K; Sasaki H; Kido M; Takahashi H; Aoki M; Egawa S
BMC Cancer; 2016 Sep; 16(1):708. PubMed ID: 27586506
[TBL] [Abstract][Full Text] [Related]
20. Risk of fracture in men with prostate cancer on androgen deprivation therapy: a population-based cohort study in New Zealand.
Wang A; Obertová Z; Brown C; Karunasinghe N; Bishop K; Ferguson L; Lawrenson R
BMC Cancer; 2015 Nov; 15():837. PubMed ID: 26525985
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
